Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, Spyre Therapeutics Inc increased its cash reserves by 419.59%, or 152.80m. Cash Flow from Financing totalled 361.08m or 40,753.61% of revenues. In addition the company used 99.91m for operations while cash used for investing totalled 108.39m.
Cash flow per share | -7.31 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 7.37 |
---|---|
Tangible book value per share | 7.37 |
More ▼
Balance sheet in USDView more
Current ratio | 19.70 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼